Hyperfractionated radiotherapy for lung cancer

Gressen, Eric

doi:10.1007/s11912-000-0013-0

Cited by 7 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, partial lung cancer cell’s resistance to radiotherapy affects therapeutic effects, and 5-year survival rate of radiotherapy alone is only 5%–10%, local recurrence occurs in 80% of patients, and metastasis occurs in 60% of patients [25]. Therefore, it is necessary to find a effective radiosensitizer to enhance tumor radiosensitivity, while with less negtive function to normal tissues.…”

Section: Discussionmentioning

confidence: 99%

Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells

et al. 2014

View full text Add to dashboard Cite

ObjectiveMyricetin, a common dietary flavonoid is widely distributed in fruits and vegetables, and is used as a health food supplement based on its immune function, anti-oxidation, anti-tumor, and anti-inflammatory properties. The aim of this study was to investigate the effects of myricetin on combination with radiotherapy enhance radiosensitivity of lung cancer A549 and H1299 cells.MethodsA549 cells and H1299 cells were exposed to X-ray with or without myricetin treatment. Colony formation assays, CCK-8 assay, flow cytometry and Caspase-3 level detection were used to evaluate the radiosensitization activity of myricetin on cell proliferation and apoptosis in vitro. Nude mouse tumor xenograft model was built to assessed radiosensitization effect of myricetin in vivo.ResultsCompared with the exposed group without myricetin treatment, the groups treated with myricetin showed significantly suppressed cell surviving fraction and proliferation, increased the cell apoptosis and increased Caspase-3 protein expression after X-ray exposure in vitro. And in vivo assay, growth speed of tumor xenografts was significantly decreased in irradiated mice treated with myricetin.ConclusionsThe study demonstrated both in vitro and in vivo evidence that combination of myricetin with radiotherapy can enhance tumor radiosensitivity of pulmonary carcinoma A549 and H1299 cells, and myricetin could be a potential radiosensitizer for lung cancer therapy.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5791518001210633

show abstract

Section: Discussionmentioning

confidence: 99%

Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Radiotherapy is a main therapeutic method for lung cancer, especially for locally advanced NSCLC [1]. However, partial lung cancer cell's resistance to radiotherapy affects therapeutic effects, and 5-year survival rate of radiotherapy alone is only 5%–10%, local recurrence occurs in 80% of patients, and metastasis occurs in 60% of patients [10]. Therefore, it is necessary to find an effective radiosensitizer to enhance tumor radiosensitivity.…”

Section: Discussionmentioning

confidence: 99%

Enhancement of Recombinant Human Endostatin on the Radiosensitivity of Human Pulmonary Adenocarcinoma A549 Cells and Its Mechanism

Jiang

Ye²,

Dai³

et al. 2012

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

We observed the effects of endostar on the radiosensitivity of pulmonary adenocarcinoma A549 cells and found that endostar inhibited A549 cell growth under normoxia and hypoxia in time and dose-dependent manners; the D0 and Dq values in control and endostar groups were (1.36 and 1.30) versus (1.019 and 1.015) under normoxia and (1.693 and 1.39) versus (2.453 and 1.026) under hypoxia, respectively; SER was 1.04 under normoxia and 1.22 under hypoxia in endostar group; under normoxia, the apoptosis rates in control, radiotherapy, endostar and combination groups were 15.9 ± 0.57%, 42.7 ± 0.37%, 19.9 ± 0.48%, and 41.5 ± 0.38%, respectively, with no significant difference between combination and radiotherapy groups; there was significant difference in G2/M phase cells between combination and radiotherapy groups (P = 0.028); under hypoxia, the apoptosis rates in the four groups were 16.7 ± 0.67%, 30.1 ± 0.95%, 26.7 ± 0.62%, and 36.3 ± 0.71%, respectively, with significant difference between combination and radiotherapy groups; G2/M phase cells were higher in combination group than radiotherapy group (P = 0.000); G2/M phase cells were higher in hypoxic combination group than in normoxic combination group (P = 0.003). Based on these results, we conclude that under hypoxia, endostar can enhance the radiosensitivity of A549 cells through G2/M arrest.

show abstract

“…Until recently, 60 Gy of radiation delivered with conventional daily fractionation was considered as standard treatment for patients undergoing primary radiotherapy with curative intent [2,21]. In patients with favorable stage III NSCLC, this yields median survival times of 9-11 months, with a 5-year overall survival rate of less than 6% [22]. Although standard radiotherapy doses have been increased to 66-70 Gy in recent years, there is no controlled evidence that these doses are superior to the 60-65 Gy standards of past years.…”

Section: Radiotherapy Schedulesmentioning

confidence: 99%

“…Thus, even if the total dose value appears lower, the delivery of the dose in a shorter time frame may increase its biologic effect. This approach is used with the intention of reducing repopulation by lung tumor cells with short potential doubling times [22]. Improved survival with hyperfractionated schedules in NSCLC specifically has yet to be demonstrated in prospective, randomized trials.…”

Section: Radiotherapy Schedulesmentioning

confidence: 99%

Docetaxel-Based Combined-Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Scagliotti

Turrisi

2003

The Oncologist

View full text Add to dashboard Cite

The cytotoxic agent docetaxel not only has proven activity in non-small cell lung cancer-when used alone or in combination-but is also a potent radiosensitizer, and improved treatments are needed in all stages of this disease. In patients with locoregionally advanced (stage III) disease, docetaxel has shown efficacy with manageable toxicities when used alone or in combination with a platinum compound in a sequential manner before localized radical radiotherapy/surgery. Presently, therapeutic gains appear to be maximized by the use of concurrent chemotherapy and irradiation. This review focuses on research with combinations of docetaxel with either cisplatin or carboplatin and radiotherapy. Overall response and survival rates to date provide data worth pursuing.

show abstract

Hyperfractionated radiotherapy for lung cancer

Cited by 7 publications

References 13 publications

Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells

Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells

Enhancement of Recombinant Human Endostatin on the Radiosensitivity of Human Pulmonary Adenocarcinoma A549 Cells and Its Mechanism

Docetaxel-Based Combined-Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About